Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration

NCT00259753 is registered in ClinicalTrials.gov with OPKO Health, Inc. as lead sponsor.

NCT NCT00259753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00259753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration
Lead sponsor
OPKO Health, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
December 31, 2007
Enrollment
120 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration